Table 4.
The result of Connectivity Map is highly dependent on probe number and probe selection
| 10 (instance ID/name) | 20 (instance ID/name) | 30 (instance ID/name) | |
|---|---|---|---|
| 1 | 450 (17-Allylamino-geldanamycin) | 607 (Butein) | 456 (Quinpirole) |
| 2 | 313 (NU-1025) | 456 (Quinpirole) | 267 (Genistein) |
| 3 | 311 (Monastrol) | 450 (17-Allylamino-geldanamycin) | 410 (Valproic acid) |
| 4 | 263 (Clofibrate) | 410 (VPA) | 703 (Genistein) |
| 5 | 606 (Thalidomide) | 317 (N-phenylanthranilic acid) | 1021 (Estradiol) |
| 6 | 611 (Geldanamycin) | 703 (Genistein) | 609 (5666823) |
| 7 | 868 (5182598) | 483 (Imatinib) | 332 (Trichostatin A) |
| 8 | 491 (Dopamine) | 413 (Trichostatin A) | 508 (Staurosporine) |
| 9 | 607 (Butein) | 1075 (Fluphenazine) | 371 (Rofecoxib) |
| 10 | 1075 (Fluphenazine) | 448 (Trichostatin A) | 389 (Wortmannin) |
Log ratios of VPA-treated versus vehicle-treated gene expression values are calculated. Probes are ranked according to the extent of differential expression. The top 10, 20 and 30 probes up- and down-regulated are picked up. Queries (10 up−10 down, 20 up−20 down, 30 up−30 down) are used to search against connectivity map, respectively. Top 10 instances positively correlated are presented in the table. (probeNum: indicates the number of up/down probes used).